2024-07-15 LIDR Meeting Notes

Hung Luu

Children’s

Riki Merrick

Vernetzt, APHL

Andrea Pitkus

UW

Pam Banning

3M - Solventum

Xavier Gansel

Biomerieux

Amy McCormick

Epic

Dan Rutz

Epic

Rob Rae

CAP

Rob Hausam

Hausam Consulting

Sandy Jones

CDC

Stan Huff

Graphite

Ed Heierman

Abbott / IICC

Andrew Quinn

Laurent Lardin

Biomerieux

Anthony Killeen

UMN

Craig Collom

Marti Velezis

 Sonrisa / FDA

Walter Sujansky

FDA

Susan Downer

JMC

Ralf Herzog

Roche

Cornelia Felder

Roche

Daniel Golson

JMC

Andrea Prada

JMC

Maria Sagat

 CAP

Raja Cholan

FDA

Russ Ott

FDA

Akila Namasivayam

FDA

Desiree Mustaquim

CDC

Christina Gallegos

APHL

John Spinosa

Lantana

Reviewing minutes from the last call - Action Item Follow up

• Pull out the definitions from LIVD for test kit and equipment and put here: SHIELD Glossary

  • Review operational definition of “equivalence”

• Outreach to Dr. DeBaca

  • Hung will check for more info and maybe see, if she could participate in SHIELD

• Keep updating the googlesheet: Potassium LIVD data

• Shared Reportable Conditions LIVD google sheet for crowdsourcing with CSTE - added sign up sheet for PHAs to specific conditions and see how that develops

• Have LIVD File Repository Requirements

  Have draft budget (for setting up a web-based database and yearly maintenance): https://aphlinformatics.atlassian.net/wiki/download/attachments/915407143/LIDR - Budget.xlsx?api=v2

• Review LIDR Use Cases and sign up to lead one of these - prioritize these use cases, so that we can finalize the requirements for the first phase of LIDR

• Define next steps to migrate existing LIVD files into FHIR LIVD catalog format and find a FHIR server to host

• Marti can share the LIDR categorical data to instance data mapping for each element for June 3, 2024

Call Schedule

send OOO via chat or email

 LIDR White Paper Review

Reviewing the comments on the LIDR White Paper = LIDR White Paper

• Discussing the corect LOINC assignment section:

  • goal here is to say be as specific as need be - Serum/Plasma would be the most commonly used LOINC system here, though for the lab they will validate and set up either Serum or Plasma, but the test would have the same LOINC, since there are very few LOINCs that are only for Serum or only for Plasma

  • XXX LOINCs may be used when the lab sets these tests up in their system, even if they mostly test on serum, but can test other sample types - in this case the expectation is that they will send the sampletype in the data exchange - this is outside of LIDR

  • Updated the sentence

• Stan’s comment mentions order codes:

  • are order codes in scope?

  • Stan was meaning the code that the provider is expecting as the performed test - the one that would include the clinical context - in the example we discussed 24 urine (which is how this test will be set up in the lab’s compendium) - which for the instrument is just urine

    • EHR-s to LIS order - 24 hr urine creatinine

    • LIS to instrument - vendor code for urine creatinine (may or may not use spot urine LOINC)

  • had discussion about use of LOINCs for orders - using LOINC only as order codes will not work, as they are often not specific enough as to the components of a panel

  • Ordering from the instrument will need to use the analyte code provided by the vendor, might get assigned a LOINC, but MUST be the vendor code

  • vendor codes may also be used to report the performed test

  • LIVD is for instrument to LIS, but if we want LIDR to support communications to/from EHR-s and LIS, then we may have to include a mapping to additional LOINCs that woudl not be provided by the manufacturers - that is the point Walter is trying to make here

Start back up here next week

ACTION ITEMS

Please see the action items at top of this page - Next deliverable is White paper draft by end of this month

Next call

Monday 7/22/2024 9 - 10 AM ET

Adjourned

 9:55 AM ET